-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Recently, the 2021 annual reports and the 2022 first quarter reports of various pharmaceutical companies have been released
.
Among them, most multinational pharmaceutical companies have achieved a year-on-year increase in performance
.
For example, the first quarterly report released by GlaxoSmithKline shows that during the reporting period, the company achieved an operating income of about 12.
3 billion US dollars, a year-on-year increase of 32%, and an operating profit of more than 3.
5 billion US dollars, a year-on-year increase of more than 60%
.
Roche also achieved double-digit sales growth of 10% in the first quarter, with revenue of $17.
2 billion
.
It is understood that Ocrevus for the treatment of multiple sclerosis and Hemlibra for the treatment of hemophilia, as well as the demand for antigen detection products in the US market, have become important factors for Roche's performance growth
.
It is worth mentioning that while the performance of a large number of companies has increased year-on-year, many multinational pharmaceutical companies have also experienced substantial growth in their performance in China
.
Recently, Novartis released its financial report for the first quarter of 2022
.
The report shows that in the first quarter, Novartis Group’s net sales increased by 5% year-on-year to $12.
5 billion
.
Among them, net sales in China increased by 16% year-on-year to US$880 million
.
At the same time, Novartis' innovative drug R&D pipeline has also made many new progress
.
In the first quarter, Sanofi's revenue growth in China also outperformed the global level.
Its revenue in the first quarter was US$10.
251 billion, an increase of 8.
6% year-on-year.
The revenue in the Chinese market reached US$955 million, an increase of 13.
4% year-on-year
.
However, Sanofi also stated that the purchase of insulin with volume is expected to be implemented in May this year, and the sales of the company's two winning products in China may drop by 30%
.
In addition to the above companies, judging from the overall financial reports of multinational pharmaceutical companies in 2021, the Chinese market has also provided important opportunities for many multinational pharmaceutical companies and contributed a lot of performance
.
For example, in fiscal year 2021, Novo Nordisk's performance in China reached 16.
019 billion Danish kroner (about 2.
547 billion US dollars), a year-on-year increase of 14%
.
It is reported that with the blessing of medical insurance, the sales of Novo Nordisk's blockbuster hypoglycemic drug liraglutide in China will be 1.
544 billion Danish kroner (about 245 million US dollars, about 1.
6 billion yuan) in 2021.
species increased by as much as 45% year-on-year
.
Another new diabetes drug, semaglutide, sold 303 million Danish kroner (about 48 million US dollars, about 300 million yuan) in just over half a year after its launch, and passed the national medical insurance negotiation last year, and the future sales will be more reliable period
.
However, while the performance of many companies in the Chinese market has increased year-on-year, there are exceptions
.
For example, in the first quarter of this year, AstraZeneca achieved a revenue of US$11.
39 billion, a year-on-year increase of 55.
6%, and a net profit of US$386 million, a year-on-year decrease of 75.
26%
.
The industry expects that, due to the continuous impact of centralized procurement and medical insurance, AstraZeneca's performance in China may experience a mid-single-digit decline in 2022
.
In general, most multinational pharmaceutical companies performed well
.
Although the profit growth rate of some companies is slowing down or decreasing, multinational pharmaceutical companies are still expanding, and they are optimistic about the development prospects of the Chinese market
.
It is reported that the person in charge of many multinational companies in China has said that the company will explore the Chinese market in a more targeted and precise manner
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, most multinational pharmaceutical companies have achieved a year-on-year increase in performance
.
For example, the first quarterly report released by GlaxoSmithKline shows that during the reporting period, the company achieved an operating income of about 12.
3 billion US dollars, a year-on-year increase of 32%, and an operating profit of more than 3.
5 billion US dollars, a year-on-year increase of more than 60%
.
Roche also achieved double-digit sales growth of 10% in the first quarter, with revenue of $17.
2 billion
.
It is understood that Ocrevus for the treatment of multiple sclerosis and Hemlibra for the treatment of hemophilia, as well as the demand for antigen detection products in the US market, have become important factors for Roche's performance growth
.
It is worth mentioning that while the performance of a large number of companies has increased year-on-year, many multinational pharmaceutical companies have also experienced substantial growth in their performance in China
.
Recently, Novartis released its financial report for the first quarter of 2022
.
The report shows that in the first quarter, Novartis Group’s net sales increased by 5% year-on-year to $12.
5 billion
.
Among them, net sales in China increased by 16% year-on-year to US$880 million
.
At the same time, Novartis' innovative drug R&D pipeline has also made many new progress
.
In the first quarter, Sanofi's revenue growth in China also outperformed the global level.
Its revenue in the first quarter was US$10.
251 billion, an increase of 8.
6% year-on-year.
The revenue in the Chinese market reached US$955 million, an increase of 13.
4% year-on-year
.
However, Sanofi also stated that the purchase of insulin with volume is expected to be implemented in May this year, and the sales of the company's two winning products in China may drop by 30%
.
In addition to the above companies, judging from the overall financial reports of multinational pharmaceutical companies in 2021, the Chinese market has also provided important opportunities for many multinational pharmaceutical companies and contributed a lot of performance
.
For example, in fiscal year 2021, Novo Nordisk's performance in China reached 16.
019 billion Danish kroner (about 2.
547 billion US dollars), a year-on-year increase of 14%
.
It is reported that with the blessing of medical insurance, the sales of Novo Nordisk's blockbuster hypoglycemic drug liraglutide in China will be 1.
544 billion Danish kroner (about 245 million US dollars, about 1.
6 billion yuan) in 2021.
species increased by as much as 45% year-on-year
.
Another new diabetes drug, semaglutide, sold 303 million Danish kroner (about 48 million US dollars, about 300 million yuan) in just over half a year after its launch, and passed the national medical insurance negotiation last year, and the future sales will be more reliable period
.
However, while the performance of many companies in the Chinese market has increased year-on-year, there are exceptions
.
For example, in the first quarter of this year, AstraZeneca achieved a revenue of US$11.
39 billion, a year-on-year increase of 55.
6%, and a net profit of US$386 million, a year-on-year decrease of 75.
26%
.
The industry expects that, due to the continuous impact of centralized procurement and medical insurance, AstraZeneca's performance in China may experience a mid-single-digit decline in 2022
.
In general, most multinational pharmaceutical companies performed well
.
Although the profit growth rate of some companies is slowing down or decreasing, multinational pharmaceutical companies are still expanding, and they are optimistic about the development prospects of the Chinese market
.
It is reported that the person in charge of many multinational companies in China has said that the company will explore the Chinese market in a more targeted and precise manner
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
